Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope(®) (biosimilar rhGH) was approved by the European Medicines Agency in 2006, with approval granted...

Descripción completa

Detalles Bibliográficos
Autores principales: Borrás Pérez, Maria Victoria, Kriström, Berit, Romer, Tomasz, Walczak, Mieczyslaw, Höbel, Nadja, Zabransky, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439985/
https://www.ncbi.nlm.nih.gov/pubmed/28553080
http://dx.doi.org/10.2147/DDDT.S130909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439985/
https://www.ncbi.nlm.nih.gov/pubmed/28553080
http://dx.doi.org/10.2147/DDDT.S130909

Ejemplares similares